Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Metcalfe

Showing results (11-20 of 64) with videos related to

Pageof 7
Sort By:
The New Zealand Medical Journal|January 29, 2003
More about cardiovascular disease and lipid management in New ZealandScott Metcalfe, Peter Moodie
The New Zealand Medical Journal|August 30, 2007
PHARMAC responds on Herceptin assumptions and decisionsScott Metcalfe, Jackie Evans
The New Zealand Medical Journal|March 7, 2007
PHARMAC and statins--correction is neededScott Metcalfe, Peter Moodie
The New Zealand Medical Journal|March 20, 2012
National prescribing data for dabigatranScott Metcalfe, Peter Moodie
The New Zealand Medical Journal|December 8, 2009
Sign On--prescribing for climate healthRochelle Phipps, Alexandra Macmillan, Scott Metcalfe, et al.
BMJ (Clinical Research Ed.)|February 11, 2003
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstatedScott Metcalfe, Sean Dougherty, Wayne McNee
The New Zealand Medical Journal|June 30, 2006
PHARMAC and EpiPen for anaphylaxisPeter Moodie, Scott Metcalfe, Sean Dougherty
The New Zealand Medical Journal|June 30, 2006
PHARMAC and erythropoietin for cancer patientsRachel Grocott, Scott Metcalfe, Peter Moodie
Pharmacoeconomics|September 12, 2014
Comment on "ahead of its time? Reflecting on New Zealand's Pharmac following its 20th anniversary" : clarification from PHARMAC: PHARMAC takes no particular distributive approach (utilitarian or otherwise)Scott Metcalfe, Rachel Grocott, Dilky Rasiah
The New Zealand Medical Journal|July 13, 2018
The Zero Carbon Bill and the health of New Zealanders-help shape this crucial health law nowAndrea Forde, Liz Springford, Scott Metcalfe
Pageof 7

Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
The New Zealand Medical Journal|January 29, 2003
More about cardiovascular disease and lipid management in New ZealandScott Metcalfe, Peter Moodie
The New Zealand Medical Journal|August 30, 2007
PHARMAC responds on Herceptin assumptions and decisionsScott Metcalfe, Jackie Evans
The New Zealand Medical Journal|March 7, 2007
PHARMAC and statins--correction is neededScott Metcalfe, Peter Moodie
The New Zealand Medical Journal|March 20, 2012
National prescribing data for dabigatranScott Metcalfe, Peter Moodie
The New Zealand Medical Journal|December 8, 2009
Sign On--prescribing for climate healthRochelle Phipps, Alexandra Macmillan, Scott Metcalfe, et al.
BMJ (Clinical Research Ed.)|February 11, 2003
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstatedScott Metcalfe, Sean Dougherty, Wayne McNee
The New Zealand Medical Journal|June 30, 2006
PHARMAC and EpiPen for anaphylaxisPeter Moodie, Scott Metcalfe, Sean Dougherty
The New Zealand Medical Journal|June 30, 2006
PHARMAC and erythropoietin for cancer patientsRachel Grocott, Scott Metcalfe, Peter Moodie
Pharmacoeconomics|September 12, 2014
Comment on "ahead of its time? Reflecting on New Zealand's Pharmac following its 20th anniversary" : clarification from PHARMAC: PHARMAC takes no particular distributive approach (utilitarian or otherwise)Scott Metcalfe, Rachel Grocott, Dilky Rasiah
The New Zealand Medical Journal|July 13, 2018
The Zero Carbon Bill and the health of New Zealanders-help shape this crucial health law nowAndrea Forde, Liz Springford, Scott Metcalfe
Pageof 7